TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03732872

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy tissue analysis
Description: biopsy samples for IHC staining and PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy tissue analysis
Description: biopsy samples for IHC staining and PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy tissue analysis
Description: biopsy samples for IHC staining and PCR
Study: NCT01024179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymer-based sirolimus-eluting stent (Partner stent )
Description: Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
Study: NCT03732872

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva analysis
Description: Saliva samples for miRNA 21 expression analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva analysis
Description: Saliva samples for miRNA 21 expression analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva analysis
Description: Saliva samples for miRNA 21 expression analysis
Study: NCT04039685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue
Description: The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue
Description: The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
Study: NCT03170869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surefire Precision Infusion System
Description: All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
Study: NCT00440609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
Study: NCT04178382

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCR-CRISPR／Cas12a detection
Description: Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
Study: NCT04169555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
Study: NCT02377388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin OR saxagliptin
Description: sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
Study: NCT02688387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
Description: The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
Description: The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
Description: The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
Description: Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
Description: Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
Study: NCT02751216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG recording + pain protocol
Study: NCT01661634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ularitide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00866645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Haloperidol
Description: 1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular Levosulpiride
Description: 2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
Study: NCT01458457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized usual care
Description: Patients get usual care from their general practitioners/specialized physicians
Study: NCT00280969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir arm
Description: Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: Patients are treated with efavirenz 300mg along with Epzicom.
Study: NCT01030887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise programme
Description: Moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise programme
Description: Moderate intensity exercise
Study: NCT00487331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture sessions 1-3 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
Study: NCT02666391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Study: NCT04346940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: 15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise brochure
Description: The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
Study: NCT01965626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 75 mg twice per day, 10 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d)
Study: NCT04691440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
Study: NCT03629106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Behavioral Coaching Session
Description: The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Behavioral Coaching Session
Description: The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
Study: NCT04155073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation, early COPD detection, electronic visit
Description: electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
Study: NCT04490473

Intervention type: OTHER
Group type: OTHER
Intervention: survey work
Description: Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
Study: NCT01708655

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat Evaporimeter measurement
Description: 1. The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~2. intracutaneous injection of 0.2 ml of atropine~3. Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~   1. Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~  2. intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~  3. intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes.
Study: NCT00132834

Intervention type: DEVICE
Intervention: R-Tube or EcoScreen
Description: Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)

Intervention type: DEVICE
Intervention: R-Tube or EcoScreen
Description: Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)

Intervention type: DEVICE
Intervention: R-Tube or EcoScreen
Description: Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
Study: NCT02076516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent: CORACTO®
Study: NCT03261024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Friction mechanics
Description: Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frictionless mechanics
Description: T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
Study: NCT02993419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus licheniformis Intervention
Description: On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo Intervention
Description: On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
Study: NCT04544137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOKS
Description: BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
Study: NCT03441139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy + Medical analgesics
Description: Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Analgesics
Description: Best analgesic therapy at investigator's discretion
Study: NCT02197208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily monitoring of LH and E2
Description: ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hCG induced natural cycle
Description: ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is \>/= 17 mm and the endometrium measures \>/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study: NCT01782287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Study: NCT00399893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide to be administered by subcutaneous injection three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered by subcutaneous injection three times daily while on study
Study: NCT01181531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Vitamin D Therapy
Description: Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
Study: NCT04296955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview as a new health communication intervention
Description: Same as intervention name
Study: NCT00745719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parathyroidectomy
Description: total parathyroidectomy with forearm autografting
Study: NCT00545688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg iv loading dose, followed by 420mg iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg iv loading dose, followed by 420mg iv 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg iv loading dose, followed by 420mg iv 3-weekly
Study: NCT02210052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency cannula
Description: Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
Study: NCT03570944

Intervention type: PROCEDURE
Intervention: HRS, KRS
Description: Elective HRS or KNR in adult patients, with any ERAS compliance
Study: NCT03872323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment
Description: The arteries injuries are repaired by endovascular treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: The arteries injuries are repaired by open surgical operation.
Study: NCT01664065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg Ceftaroline fosamil
Description: 1 h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg Ceftaroline fosamil
Description: 1 h infusion